Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Completed

• Conditions: Hypercholesterolemia; Coronary Heart Disease

• Registration Number: NCT00396110
• Lead Sponsor: AstraZeneca

Brief Summary

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C \< 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Status Verified: 2003-02
• Study Start: 2003-02
• Study First Submitted: 2006-11-03
• Study First Submitted QC: 2006-11-03
• Last Update Submitted: 2006-11-03
• Study First Posted: 2006-11-06
• Last Update Posted: 2006-11-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3889

Inclusion Criteria

• High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
• Patients were aged >18 years and <70 years (men) and < 75 years (women).

Read More

Exclusion Criteria

• Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
• Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified